Top of the morning to you. Another busy day is unfolding here on the Pharmalot campus, where we are mulling over our cluttered calendar and plotting our next moves. No doubt, you can relate. After all, this is only the middle of the week and there is so much to be done. This calls, as you may imagine, for a hot cup of stimulation. We are sticking with almond toffee for now, by the way. Feel free to join us. Meanwhile, here are some tidbits. The world is a busy place, yes? Hope you make your way today …

Pfizer (PFE) has agreed to pay up to $636 million for the rights to gene therapies under development at Vivet Therapeutics, The Wall Street Journal says. Gene therapies, which introduce new DNA into the body to address diseases caused by a single faulty gene, are attracting attention for their ability to cure intractable diseases. In the past month, both Roche (RHHBY) and Biogen (BIIB) have made bets on gene therapy. Vivet’s most advanced program is a gene therapy for Wilson disease, a rare, inherited liver disorder that causes the buildup of copper in the body.

Continue to STAT Plus to read the full story…

Source link